Antidrug Antibody Formation in Oncology: Clinical Relevance and Challenges
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
In oncology, an increasing number of targeted anticancer agents and immunotherapies are of biological origin. These biological drugs may trigger immune responses that lead to the formation of antidrug antibodies (ADAs). ADAs are directed against immunogenic parts of the drug and may affect efficacy and safety. In other medical fields, such as rheumatology and hematology, the relevance of ADA formation is well established. However, the relevance of ADAs in oncology is just starting to be recognized, and literature on this topic is scarce. In an attempt to fill this gap in the literature, we provide an up-to-date status of ADA formation in oncology. In this focused review, data on ADAs was extracted from 81 clinical trials with biological anticancer agents. We found that most biological anticancer drugs in these trials are immunogenic and induce ADAs (63%). However, it is difficult to establish the clinical relevance of these ADAs. In order to determine this relevance, the possible effects of ADAs on pharmacokinetics, efficacy, and safety parameters need to be investigated. Our data show that this was done in fewer than 50% of the trials. In addition, we describe the incidence and consequences of ADAs for registered agents. We highlight the challenges in ADA detection and argue for the importance of validating, standardizing, and describing well the used assays. Finally, we discuss prevention strategies such as immunosuppression and regimen adaptations. We encourage the launch of clinical trials that explore these strategies in oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IgG Subclasses and Allotypes: From Structure to Effector Functions
Vidarsson, G., Dekkers, G., & Rispens, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00520 · Cited by 2,667
Yu, A. L., Uttenreuther-Fischer, M. M., Huang, C. S., Tsui, C. C., Gillies, S. D., Reisfeld, R. A., & Kung, F. H. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2169 · Cited by 250
Cited by
Advances in immunotherapy for hepatocellular carcinoma
Sangro, B., Sarobe, P., Hervás-Stubbs, S., & Melero, I. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00438-0 · Cited by 1,306
Wrangle, J. M., Velcheti, V., Patel, M. R., Garrett-Mayer, E., Hill, E. G., Ravenel, J. G., Miller, J. S., Farhad, M., Anderton, K., Lindsey, K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30148-7 · Cited by 412
Mechanisms of drug resistance in HCC
Ladd, A. D., Duarte, S., Sahin, I., & Zarrinpar, A. (2024) · Hepatology · doi:10.1097/hep.0000000000000237 · Cited by 363
Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors
Centanni, M., Moes, D. J. A. R., Trocóniz, I. F., Ciccolini, J., & van Hasselt, J. G. C. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00748-2 · Cited by 355
Mason, D. M., Friedensohn, S., Weber, C. R., Jordi, C., Wagner, B., Meng, S. M., Ehling, R. A., Bonati, L., Dahinden, J., Gainza, P., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00699-9 · Cited by 308
Metadata
- Authors
- van Brummelen, E. M. J., Ros, W., Wolbink, G., Beijnen, J. H., & Schellens, J. H. M.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2016-07-20
- Volume
- 21
- Issue
- 10
- Pages
- 1260-1268
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2475781394
- Cited by
- 150
- References
- 2
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.